Related references
Note: Only part of the references are listed.Epidemiology of lung cancer and lung cancer screening programs in China and the United States
Dawei Yang et al.
CANCER LETTERS (2020)
Unraveling cancer lineage drivers in squamous cell carcinomas
Yinglu Guan et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Cancer burden of major cancers in China: A need for sustainable actions
Maomao Cao et al.
CANCER COMMUNICATIONS (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China
Xiaoyou Li et al.
CLINICAL THERAPEUTICS (2019)
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer
Stephen J. Bagley et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Y. -L. Wu et al.
ANNALS OF ONCOLOGY (2019)
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Ryota Tamura et al.
CANCER SCIENCE (2019)
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting
Katherine B. Winfree et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China
Fei Qi et al.
CHINESE JOURNAL OF CANCER RESEARCH (2019)
Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
Yasuhiro Tsutani et al.
BMC CANCER (2018)
Personalized therapy for lung cancer: Striking a moving target
Suchita Pakkala et al.
JCI INSIGHT (2018)
Bevacizumab in advanced lung cancer: state of the art
Sandra Assoun et al.
FUTURE ONCOLOGY (2017)
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer
Masato Karayama et al.
EUROPEAN JOURNAL OF CANCER (2016)
Recent Advances in Immunotherapy in Metastatic NSCLC
Pranshu Bansal et al.
FRONTIERS IN ONCOLOGY (2016)
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Oliver Gautschi et al.
CLINICAL LUNG CANCER (2015)
High circulating VEGF level predicts poor overall survival in lung cancer
Pingping Hu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Share Paper
